Ocugen, Inc. (OCGN)
Pre-Market:
| Previous Close | 2.0600 |
| Open | 1.9900 |
| Bid | 2.2700 x 3200 |
| Ask | 2.2800 x 2200 |
| Day's Range | 1.9700 - 2.2800 |
| 52 Week Range | 1.6700 - 17.6500 |
| Volume | |
| Avg. Volume | 11,009,582 |
| Market Cap | 483.083M |
| Beta (5Y Monthly) | 4.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3470 |
| Earnings Date | Aug 04, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.38 |
- Motley Fool
Is Ocugen Finally on the Way to Vaccine Revenue?
Last year, Ocugen (NASDAQ: OCGN) shares soared more than 700% over just a few days. The company signed an agreement to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. The companies later added rights in Canada to the agreement too. Bharat's product -- Covaxin -- already had gained emergency authorization in its home country of India.
- Motley Fool
Where Will Ocugen Be in 1 Year?
The past 18 months have been a roller coaster for Ocugen (NASDAQ: OCGN). Shares of the biotech company skyrocketed in early 2021 after it announced an agreement with India-based Bharat Biotech. The deal stipulated that Ocugen would hold the right to commercialize the Covaxin coronavirus vaccine, which was originally developed by Bharat Biotech, in the U.S. and Canada.
- Motley Fool
Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript
With me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide a financial update. Earlier this morning, we issued a press release, including a business update and first-quarter financial results for 2022.
